Table 2 Prognostic value of early phase circulating GSTA2 protein in HCC recipients after liver transplantation.

Early phase plasma GSTA2 protein (high vs. low)

45.8

85.4

0.70 (0.57–0.83)

0.003**

9.034

0.002**

Milan Criteria (beyond vs. within)

83.3

67.1

0.75 (0.65–0.86)

0.000***

1.046

0.966

UCSF criteria (beyond vs. within)

75.0

82.9

0.79 (0.68–0.90)

0.000***

7.532

0.035*

Tumor size (≥3 cm vs. <3 cm)

82.6

52.4

0.68 (0.56–0.79)

0.010**

3.148

0.141

Vascular permeation (yes vs. no)

59.1

79.3

0.69 (0.56–0.82)

0.006**

3.773

0.062

Pre-OT AFP level (≥400 ng/ml vs. <400 ng/ml)

33.3

88.9

0.61 (0.47–0.75)

0.097

N/A

Graft weight to recipient ESLV (<60% vs. >60%)

75.0

37.8

0.56 (0.44–0.69)

0.342

N/A

Type of transplant (LDLT vs. DDLT)

79.2

24.4

0.52 (0.39–0.65)

0.792

N/A

Tumor number (>3 vs. <3)

34.8

89.0

0.62 (0.48–0.76)

0.082

N/A

Differentiation (poor vs. well)

23.8

94.9

0.59 (0.45–0.74)

0.190

N/A

Plasma GSTA2 protein (high vs. low)

2.24 (1.13–4.45)

0.021*

1.75 (0.81–3.75)

0.154

Sex (male vs. female)

1.04 (0.43–2.51)

0.928

Age (≤55 yr vs. <55 yr)

1.06 (0.54–2.08)

0.860

Serum AFP (>400 ng/ml vs. ≤400 ng/ml)

2.89 (1.37–6.07)

0.005**

1.73 (0.70–4.26)

0.234

Tumor size (>3 cm vs. ≤3 cm)

1.96 (0.95–4.02)

0.068

Tumor number (>3 vs. ≤3)

2.00 (0.09–4.44)

0.088

Vascular permeation (yes vs. no)

2.36 (1.19–4.68)

0.014*

1.246 (0.54–2.87)

0.606

Differentiation (poor vs. well)

3.08 (1.26–7.54)

0.013*

1.90 (0.73–4.95)

0.191

UCSF criteria (beyond vs. within)

4.22 (2.13–8.37)

0.000***

2.30 (1.00–5.31)

0.050

Milan Criteria (beyond vs. within)

3.09 (1.53–5.25)

0.002**

N/A

Type of LT (DDLT vs. LDLT)

1.30 (0.61–2.78)

0.500

N/A

Graft size (>60% vs. ≤60%)

0.75 (0.38–1.47)

0.402

N/A